XML 25 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended 0 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Feb. 07, 2012
Enobia Pharma Corp. [Member]
Sep. 30, 2012
Enobia Pharma Corp. [Member]
Sep. 30, 2012
Enobia Pharma Corp. [Member]
Sep. 30, 2012
Taligen Therapeutics Inc Member
Sep. 30, 2011
Taligen Therapeutics Inc Member
Sep. 30, 2012
Taligen Therapeutics Inc Member
Sep. 30, 2011
Taligen Therapeutics Inc Member
Jan. 28, 2011
Taligen Therapeutics Inc Member
Sep. 30, 2012
Orphatec Pharmaceuticals Gmbh Member
Sep. 30, 2011
Orphatec Pharmaceuticals Gmbh Member
Sep. 30, 2012
Orphatec Pharmaceuticals Gmbh Member
Sep. 30, 2011
Orphatec Pharmaceuticals Gmbh Member
Feb. 08, 2011
Orphatec Pharmaceuticals Gmbh Member
Feb. 07, 2012
Minimum [Member]
Enobia Pharma Corp. [Member]
Jan. 28, 2011
Minimum [Member]
Taligen Therapeutics Inc Member
Feb. 08, 2011
Minimum [Member]
Orphatec Pharmaceuticals Gmbh Member
Feb. 07, 2012
Maximum [Member]
Enobia Pharma Corp. [Member]
Jan. 28, 2011
Maximum [Member]
Taligen Therapeutics Inc Member
Feb. 08, 2011
Maximum [Member]
Orphatec Pharmaceuticals Gmbh Member
Feb. 07, 2012
In Process Research And Development Member
Enobia Pharma Corp. [Member]
Sep. 30, 2012
Enobia Pharma Corp. [Member]
Business Acquisition [Line Items]                                                    
Business acquisition, cash paid           $ 623,876             $ 111,773         $ 3,050                
Business Acquisition, Percentage of Voting Interests Acquired           100.00%                                        
Business acquisition, additional contingent payments                                     0 0 0 470,000 367,000 42,000    
Contingent consideration 139,453   139,453   18,120 117,000 122,444 122,444 9,615   9,615     7,394   7,394                    
Industrial index rate for discounting contingent consideration cash flows           5.20%                                        
Weighted Average Cost Of Capital Used In Discounting Contingent Consideration Cash Flows           13.00%                                        
Intangible assets not amortizable                                                 587,000  
Rate of return on historical costs           13.00%                                        
Deferred tax liabilities           31,665                                        
Deferred tax liabilities, intangible assets           78,620                                        
Deferred tax assets, tax credit carryforwards           46,955                                        
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized               6,794                                    
Estimated fair value of contingent consideration           117,000             11,634         5,086                
Change in fair value of contingent consideration             1,932 5,444 (4,224) 149 (3,069) 899   1,750 87 1,958 218                  
Gain related to change of fair value assumptions                 4,331   4,331                              
Acquisition-related costs $ 967 $ 236 $ 19,447 $ 11,164     $ 3,400 $ 20,600                                   $ 7,900